本文選題：結直腸癌　切入點：EGFR抑制劑　出處：《河北醫(yī)科大學》2017年碩士論文

【摘要】：結直腸癌是最常見的惡性腫瘤之一。隨著分子生物學技術飛速發(fā)展,以分子靶向治療為主的個體化治療在結直腸癌治療中占據(jù)了重要的地位。近年來,作用于EGFR、VEGF和c-Met等位點的新型靶向藥物不斷進入臨床試驗,層出不窮的研究在不停地探索靶向藥物聯(lián)合傳統(tǒng)化療、免疫治療以及不同靶向藥物聯(lián)合使用的療效,以期通過高效低毒的治療手段為患者帶來最大的生存獲益。本文總結了近年來結直腸癌分子靶向治療的臨床新進展,并對靶向藥物的發(fā)展趨勢進行了展望。
[Abstract]:Colorectal cancer is one of the most common malignant tumors.With the rapid development of molecular biology technology, individualized therapy with molecular targeted therapy plays an important role in the treatment of colorectal cancer.In recent years, new targeting drugs acting on the allelic sites of EGFR and c-Met have been continuously introduced into clinical trials, and numerous studies have been carried out to explore the efficacy of targeting drugs in combination with traditional chemotherapy, immunotherapy and combination of different targeted drugs.In order to achieve maximum survival benefits through effective and low-toxic treatment.In this review, the recent advances in molecular targeted therapy for colorectal cancer were reviewed, and the development trend of targeted drugs was prospected.
【學位授予單位】：河北醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R735.34

【參考文獻】

相關期刊論文 前2條

1 Yoshihito Ohhara;Naoki Fukuda;Satoshi Takeuchi;Rio Honma;Yasushi Shimizu;Ichiro Kinoshita;Hirotoshi Dosaka--Akita;;Role of targeted therapy in metastatic colorectal cancer[J];World Journal of Gastrointestinal Oncology;2016年09期

2 Yu-Wen Zhang;;Promise and challenges on the horizon of MET-targeted cancer therapeutics[J];World Journal of Biological Chemistry;2015年02期

，

本文編號：1709404